BR122019022434B8 - método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular - Google Patents

método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular

Info

Publication number
BR122019022434B8
BR122019022434B8 BR122019022434A BR122019022434A BR122019022434B8 BR 122019022434 B8 BR122019022434 B8 BR 122019022434B8 BR 122019022434 A BR122019022434 A BR 122019022434A BR 122019022434 A BR122019022434 A BR 122019022434A BR 122019022434 B8 BR122019022434 B8 BR 122019022434B8
Authority
BR
Brazil
Prior art keywords
mammalian cells
heterologous protein
cell culture
culture supernatant
culturing mammalian
Prior art date
Application number
BR122019022434A
Other languages
English (en)
Other versions
BR122019022434B1 (pt
Inventor
Giovagnoli Andre
Roy Sylvain
Ducros Veronique
Charlot Virginie
Stauffer Yves-Olivier
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Priority claimed from BRPI0821481-6A external-priority patent/BRPI0821481B1/pt
Publication of BR122019022434B1 publication Critical patent/BR122019022434B1/pt
Publication of BR122019022434B8 publication Critical patent/BR122019022434B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

cultivar células de mamífero que secretam proteína heteróloga, tais como células cho ou bhk, de 35,1 a 36,5 °c e/ou em ph 7,15 a 7,20 e/ou em uma concentração de co2 dissolvido de 10 % ou menor. as proteínas heterólogas preferidas são fator viii, adamts-13, furina ou fator vii.
BR122019022434A 2007-12-27 2008-12-22 método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular BR122019022434B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US932807P 2007-12-27 2007-12-27
US61/009328 2007-12-27
BRPI0821481-6A BRPI0821481B1 (pt) 2007-12-27 2008-12-22 Método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
PCT/US2008/088036 WO2009086309A2 (en) 2007-12-27 2008-12-22 Cell culture processes

Publications (2)

Publication Number Publication Date
BR122019022434B1 BR122019022434B1 (pt) 2020-11-03
BR122019022434B8 true BR122019022434B8 (pt) 2021-07-27

Family

ID=40350258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR122019022434A BR122019022434B8 (pt) 2007-12-27 2008-12-22 método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular

Country Status (21)

Country Link
US (2) US9359629B2 (pt)
EP (4) EP2574676B1 (pt)
JP (3) JP5727790B2 (pt)
KR (4) KR101818411B1 (pt)
CN (2) CN101910408A (pt)
AR (2) AR069956A1 (pt)
AU (1) AU2008345231B2 (pt)
BR (1) BR122019022434B8 (pt)
CA (1) CA2709890A1 (pt)
DK (3) DK2574676T3 (pt)
ES (3) ES2649094T3 (pt)
HK (1) HK1246827A1 (pt)
HR (3) HRP20171375T1 (pt)
HU (2) HUE036712T2 (pt)
MX (2) MX343271B (pt)
NZ (1) NZ586250A (pt)
PL (3) PL2574677T3 (pt)
PT (3) PT2574677T (pt)
SG (2) SG187397A1 (pt)
SI (3) SI2574677T1 (pt)
WO (1) WO2009086309A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MY185872A (en) 2006-09-13 2021-06-14 Abbvie Inc Cell culture improvements
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
KR101808496B1 (ko) * 2009-07-31 2017-12-12 백스터 인터내셔널 인코포레이티드 Adamts 단백질 발현을 위한 세포 배양 배지
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US20140051832A1 (en) * 2011-03-11 2014-02-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX2016012288A (es) * 2014-03-25 2017-01-23 Genentech Inc Metodos para preparar un poloxamero para usar en medio de cultivo celular.
KR20160144429A (ko) * 2014-04-10 2016-12-16 바이엘 헬쓰케어 엘엘씨 배합된 배지 분말 제형 및 세포 배양을 위한 액체 배지의 제조 방법
AU2015270137A1 (en) * 2014-06-03 2016-12-22 Lupin Limited Cell culture process for producing a protein
MX2016015944A (es) 2014-06-04 2017-08-15 Amgen Inc Metodos para cosechar cultivos de celulas de mamifero.
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
CN109952370B (zh) * 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
CN114657118B (zh) * 2021-12-31 2023-12-01 广州齐志生物工程设备有限公司 一种2bs细胞在生物反应器内的多倍放大方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4921792A (en) * 1987-11-27 1990-05-01 Miles Inc. Continuous cell dispersion, cultivation and substance recovery process
JPH0787799B2 (ja) * 1988-03-30 1995-09-27 森永製菓株式会社 モノクローナル抗体生産増強法
US6100050A (en) 1989-08-17 2000-08-08 Dade Behring Ag Factor VIII:Ca chromogenic assay
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
ES2109336T3 (es) 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
HU218890B (hu) 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AU1333797A (en) * 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
WO1998000521A1 (fr) * 1996-06-28 1998-01-08 The Green Cross Corporation Milieux exempts de serum, methode de culture de cellules d'origine animale, et procede de production de substances physiologiquement actives
US5854021A (en) 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
BR0008405B1 (pt) 1999-02-22 2014-04-22 Baxter Int Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
AU780415B2 (en) 1999-07-13 2005-03-17 Biovitrum Ab Stable Factor VIII compositions
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
SE518174C2 (sv) * 1999-11-16 2002-09-03 Appliedsensor Sweden Ab Detektionsförfarande av oönskad mikrobiell infektion i animaliecellodling
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
MXPA03008590A (es) 2001-03-22 2003-12-08 Novo Nordisk Healthcare Ag Derivados del factor vii de coagulacion.
JP2003047461A (ja) * 2001-07-31 2003-02-18 Astec:Kk アパタイトシ−トを用いた細胞の高密度細胞培養法及び培養装置、細胞培養モジュール
CA2458980C (en) * 2001-08-31 2012-10-30 Bayer Healthcare Ag A unit and a process for carrying out high cell density fermentation
JP4537059B2 (ja) 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
JP4351049B2 (ja) * 2001-10-02 2009-10-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核細胞中で組換えタンパク質を生産する方法
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US20030119723A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
PT2287288E (pt) * 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
WO2004092218A1 (ja) * 2003-04-17 2004-10-28 Mitsubishi Pharma Corporation 組換えアンチトロンビンの製造方法
WO2005095578A1 (en) * 2004-03-05 2005-10-13 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
ES2380485T3 (es) * 2005-02-11 2012-05-14 Novo Nordisk Health Care Ag Producción de un polipéptido en un líquido de cultivo sin suero con hidrolizado de proteínas vegetales
EP1974014B1 (en) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptide-free cell culture media
JP5485873B2 (ja) 2007-05-22 2014-05-07 バクスター・インターナショナル・インコーポレイテッド ヒトフューリンのための予備的な精製方法

Also Published As

Publication number Publication date
EP2574677B1 (en) 2017-09-13
HRP20171375T1 (hr) 2017-12-15
JP2011507551A (ja) 2011-03-10
PL2574676T3 (pl) 2017-12-29
ES2644089T3 (es) 2017-11-27
PL2574677T3 (pl) 2017-12-29
EP2574676A1 (en) 2013-04-03
PT2574676T (pt) 2017-10-11
WO2009086309A3 (en) 2009-10-01
AU2008345231B2 (en) 2014-09-11
EP2574677A1 (en) 2013-04-03
KR20170126514A (ko) 2017-11-17
ES2649094T3 (es) 2018-01-10
PL2235197T3 (pl) 2018-01-31
AU2008345231A1 (en) 2009-07-09
HUE036496T2 (hu) 2018-07-30
AR069956A1 (es) 2010-03-03
KR101818411B1 (ko) 2018-01-12
MX343269B (es) 2016-10-31
US20160244506A1 (en) 2016-08-25
CN101910408A (zh) 2010-12-08
EP2574676B1 (en) 2017-08-30
JP5890854B2 (ja) 2016-03-22
SI2574676T1 (sl) 2017-10-30
NZ586250A (en) 2012-11-30
AR110864A2 (es) 2019-05-08
CN106222220A (zh) 2016-12-14
ES2647294T3 (es) 2017-12-20
EP2235197B1 (en) 2017-07-26
HUE036712T2 (hu) 2018-07-30
MX343271B (es) 2016-10-31
KR101798813B1 (ko) 2017-11-16
WO2009086309A2 (en) 2009-07-09
EP3255152A1 (en) 2017-12-13
DK2235197T3 (en) 2017-10-09
PT2235197T (pt) 2017-10-11
JP2016013140A (ja) 2016-01-28
BRPI0821481A2 (pt) 2014-11-04
PT2574677T (pt) 2017-10-19
SI2574677T1 (sl) 2017-11-30
DK2574676T3 (en) 2017-10-09
KR20180005287A (ko) 2018-01-15
SG10201503304RA (en) 2015-06-29
CA2709890A1 (en) 2009-07-09
SI2235197T1 (sl) 2017-10-30
HRP20171495T1 (hr) 2018-01-26
EP2235197A2 (en) 2010-10-06
KR20100097752A (ko) 2010-09-03
KR101659458B1 (ko) 2016-09-23
US9359629B2 (en) 2016-06-07
BR122019022434B1 (pt) 2020-11-03
HRP20171374T1 (hr) 2017-12-29
US20090176269A1 (en) 2009-07-09
SG187397A1 (en) 2013-02-28
HK1246827A1 (zh) 2018-09-14
DK2574677T3 (da) 2017-11-06
JP5727790B2 (ja) 2015-06-03
KR20160112025A (ko) 2016-09-27
JP2014100148A (ja) 2014-06-05

Similar Documents

Publication Publication Date Title
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
BR112015023424A2 (pt) construto de expressão engenheirado, método para aprimoramento de produção de rna ou proteína, vetor, célula, hospedeira bacteriana, sistema de cultura de célula para síntese in vivo de dsrna, composição e método para controlar uma infestação de pragas de invertebrados ou para inibir a propagação de uma doença viral em uma população de plantas, e terminador transcricional
ATE490336T1 (de) Verfahren zur verbesserten isolierung rekombinant produzierter proteine
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
ATE549395T1 (de) Medium und kultur von embryonalen stammzellen
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
PE20081655A1 (es) Medios racionalmente disenados para cultivo celular
SA516371797B1 (ar) تركيبة وطريقة لثبات الأحماض النووية في عينات بيولوجية
MX2009011362A (es) Uso de temperatura baja y/o ph bajo en el cultivo celular.
ATE414144T1 (de) Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
SG169359A1 (en) A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
AR060841A1 (es) Produccion de etanol en hospedantes no recombinantes
DK1720979T3 (da) Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
WO2011091350A3 (en) Methods & compositions for improving protein production
CO7240396A2 (es) Purificación de iduronato-2-sulfatasa
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
DK1495112T3 (da) Cellekulturmedium
ATE532868T1 (de) Apoptose induzierende positivkontrolle für expressionsmodulationsexperimente
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
MX2011009023A (es) Metodos para seleccionar celulas eucarioticas que expresan una proteina heterologa.
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
EA200900984A1 (ru) Улучшение клеточного роста

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2639 DE 03/08/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)